PreAxia's Loss Skyrockets Amid R&D Push, Going Concern Doubts Persist

TL;DR

**PAXH is a speculative bet on future development with no current revenue and a rapidly expanding loss, making it a high-risk play for traders.**

AI Summary

PREAXIA HEALTH CARE PAYMENT SYSTEMS INC. (PAXH) reported no revenue for the three months ended August 31, 2025, consistent with the prior year. The company experienced a significant increase in net comprehensive loss, rising to $874,906 for the three months ended August 31, 2025, compared to a loss of $4,627 for the same period in 2024. This substantial increase in loss was primarily driven by a surge in operating expenses, which totaled $875,203 for the quarter, up from $4,627 in the prior year. Key expense increases include $391,263 in research and development, $387,500 in management and labor, and $65,000 in consulting. The company's cash and cash equivalents increased to $130,285 as of August 31, 2025, from zero at May 31, 2025, largely due to $200,000 from stock subscriptions for cash and $1,643,397 from stock subscriptions issued for debt. Total assets grew to $1,150,285 from zero, while total liabilities decreased significantly to $722,963 from $2,341,169, primarily due to a reduction in related party loans from $1,627,421 to $100,438. The company's accumulated deficit expanded to $6,085,524, and it continues to operate in the development stage with substantial doubt about its ability to continue as a going concern.

Why It Matters

This 10-Q/A filing reveals PREAXIA HEALTH CARE PAYMENT SYSTEMS INC. is burning cash rapidly in its development stage, with a net comprehensive loss of $874,906 and zero revenue. For investors, this signals extreme risk, as the company's ability to continue as a going concern is in substantial doubt, relying heavily on future capital infusions. Employees face uncertainty given the lack of revenue and ongoing losses. Customers are not yet impacted as products are still in development, but the company's financial instability could hinder future offerings. In a competitive healthcare payment and personal financial management market, PreAxia's inability to generate revenue and its significant accumulated deficit of $6,085,524 place it at a severe disadvantage against established players.

Risk Assessment

Risk Level: high — The company incurred a net comprehensive loss of $874,906 for the three months ended August 31, 2025, and has an accumulated deficit of $6,085,524. These factors, coupled with zero revenue and the explicit 'Going Concern' disclosure, indicate a very high risk of financial instability and potential failure.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Given the 'Going Concern' warning and lack of revenue, it is advisable to avoid PAXH until there is clear evidence of revenue generation and a sustainable business model.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$1,150,285

total Debt

$722,963

net Income

-$874,906

eps

N/A

gross Margin

N/A

cash Position

$130,285

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $0 — Revenue (for the three months ended August 31, 2025 and 2024, indicating no operational income)
• $874,906 — Net Comprehensive Loss (for the three months ended August 31, 2025, a significant increase from $4,627 in 2024)
• $875,203 — Total Operating Expenses (for the three months ended August 31, 2025, up from $4,627 in 2024)
• $391,263 — Research and Development Expenses (for the three months ended August 31, 2025, compared to $0 in 2024)
• $6,085,524 — Accumulated Deficit (as of August 31, 2025, indicating substantial historical losses)
• $130,285 — Cash and Cash Equivalents (as of August 31, 2025, up from $0 at May 31, 2025)
• 54,314,782 — Outstanding Shares of Common Stock (as of October 15, 2025, corrected in this 10-Q/A filing)
• $74,801 — Cash Used in Operating Activities (for the three months ended August 31, 2025, reflecting ongoing cash burn)
• $427,322 — Total Shareholders' Equity (as of August 31, 2025, a positive shift from a deficit of $2,341,169 at May 31, 2025, largely due to stock subscriptions)
• $1,643,397 — Stock Subscription Issued for Debt (a non-cash financing activity for the three months ended August 31, 2025)

Key Players & Entities

• PREAXIA HEALTH CARE PAYMENT SYSTEMS INC. (company) — registrant
• Tiempo de Mexico Ltd. (company) — acquired subsidiary
• PreAxia Health Care Payment Ltd. (company) — wholly owned subsidiary
• Zane Inc. CA (company) — wholly owned subsidiary created May 23, 2025
• Zane Inc US (company) — wholly owned subsidiary created September 10, 2025
• SEC (regulator) — Securities and Exchange Commission
• $874,906 (dollar_amount) — net comprehensive loss for Q3 2025
• $6,085,524 (dollar_amount) — accumulated deficit as of August 31, 2025
• $391,263 (dollar_amount) — research and development expenses for Q3 2025
• $130,285 (dollar_amount) — cash and cash equivalents as of August 31, 2025

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has a substantial accumulated deficit of $6,085,524 and experienced a significant increase in net comprehensive loss to $874,906 for the three months ended August 31, 2025. This, coupled with a cash burn from operations, raises substantial doubt about its ability to continue as a going concern.
• High Operating Expense Growth [high — operational]: Total operating expenses surged to $875,203 for the three months ended August 31, 2025, from $4,627 in the prior year. This 18,600% increase is driven by significant investments in R&D ($391,263) and management/labor ($387,500), which are not yet generating revenue.
• Dependence on Financing Activities [medium — financial]: The company's cash position improved to $130,285 due to $200,000 from stock subscriptions for cash and $1,643,397 from stock subscriptions issued for debt. This highlights a reliance on external financing rather than operational revenue.
• Accumulated Deficit [medium — financial]: The accumulated deficit has grown to $6,085,524 as of August 31, 2025. This indicates that the company has historically incurred more expenses than revenues, a common characteristic of development-stage companies.
• Development Stage Operations [medium — operational]: The company is in the development stage, with no revenue generated in the reported periods. This implies a long path to commercialization and profitability, with ongoing risks associated with product development and market acceptance.

Industry Context

The healthcare payment systems industry is highly competitive and rapidly evolving, driven by technological advancements and regulatory changes. Companies in this space typically require significant investment in R&D and robust compliance frameworks to succeed. PAXH appears to be in the early stages of developing its solution within this complex environment.

Regulatory Implications

As a healthcare payment systems company, PAXH is subject to stringent regulations concerning data privacy (e.g., HIPAA) and financial transactions. Failure to comply with these regulations can result in significant fines and reputational damage, adding another layer of risk to its development efforts.

What Investors Should Do

1. Monitor R&D progress and future revenue generation
2. Evaluate cash burn rate and future financing needs
3. Assess management's strategy for achieving profitability

Key Dates

• 2025-08-31: End of Second Quarter — Reported $0 revenue and a net comprehensive loss of $874,906, with operating expenses of $875,203.
• 2025-05-31: End of First Quarter — Reported $0 cash and cash equivalents, and total assets of $0.
• 2025-10-15: Filing Date of 10-Q/A — Corrected outstanding shares of common stock to 54,314,782.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company's historical unprofitability, standing at $6,085,524 as of August 31, 2025.)

Going Concern

An assumption that a company will continue to operate for the foreseeable future, typically at least 12 months. (Substantial doubt exists for PAXH due to its financial performance and cash burn, impacting investor confidence.)

Stock Subscription Issued for Debt

A non-cash transaction where a company issues its stock in exchange for settling outstanding debt. (PAXH utilized this to raise $1,643,397 in value, impacting its balance sheet without an immediate cash inflow.)

Development Stage

A company that is developing a new product or service and has not yet generated significant revenue. (PAXH is in this stage, explaining the lack of revenue and high R&D expenses.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, PREAXIA HEALTH CARE PAYMENT SYSTEMS INC. (PAXH) shows a dramatic increase in its net comprehensive loss, rising from $4,627 to $874,906. This is directly attributable to a surge in operating expenses, which grew from $4,627 to $875,203, driven by substantial investments in research and development and management. While total assets have increased significantly from zero to $1,150,285, this is largely due to financing activities, not operational success, as revenue remains at $0.

Key Financial Figures

• $0.001 — ection 12(g) of the Act: Common Stock, $0.001 par value (Title of class) Indicate
• $0 — s research and development expenses and $0 in the three months ended August 31, 20

Filing Documents

• paxh_10qa-083125.htm (10-Q/A) — 413KB
• ex31x1.htm (EX-31.1) — 8KB
• ex32x1.htm (EX-32.1) — 4KB
• 0001079973-25-001640.txt ( ) — 2938KB
• paxh-20250831.xsd (EX-101.SCH) — 27KB
• paxh-20250831_cal.xml (EX-101.CAL) — 36KB
• paxh-20250831_def.xml (EX-101.DEF) — 95KB
• paxh-20250831_lab.xml (EX-101.LAB) — 235KB
• paxh-20250831_pre.xml (EX-101.PRE) — 199KB
• paxh_10qa-083125_htm.xml (XML) — 304KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 1

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS 1

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 2

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 6

CONTROLS AND PROCEDURES

ITEM 4. CONTROLS AND PROCEDURES 6

– OTHER INFORMATION

PART II – OTHER INFORMATION 6

LEGAL PROCEEDINGS

ITEM 1. LEGAL PROCEEDINGS 6

RISK FACTORS

ITEM 1A. RISK FACTORS 6

CYBER SECURITY

ITEM 1C CYBER SECURITY 6

UNREGISTERED SALES OF EQUITY SECURITIES

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 6

DEFAULTS UPON SENIOR SECURITIES

ITEM 3. DEFAULTS UPON SENIOR SECURITIES 6

MINE SAFETY DISCLOSURES

ITEM 4. MINE SAFETY DISCLOSURES 6

OTHER INFORMATION

ITEM 5. OTHER INFORMATION 6

SIGNATURES

SIGNATURES 8 1 PART I - FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Article 210 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal recurring nature. Operating results for the three-month period ended August 31, 2025 are not necessarily indicative of the results that may be expected for the fiscal year ended May 31, 2026. For further information refer to the consolidated financial statements and footnotes thereto included in PreAxia's Annual Report on Form 10-K for the year ended May 31, 2025. Page Unaudited Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets as of August 31, 2025 (unaudited) and May 31, 2025 F-1 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended August 31, 2025 and 2024 F-2 Unaudited Condensed Consolidated Statements of Changes in Stockholders' Deficit for the three months ended August 31, 2025 and 2024 F-3 Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended August 31, 2025 and 2024 F-4 Notes to Unaudited Condensed Consolidated Financial Statements F-5 F-1 PreAxia Health Care Payment Systems Inc . Condensed Consolidated Balance Sheets As of August 31, 2025, and May 31, 2025 August 31, 2025 May 31, 2025 Assets (Unaudited) Current assets Cash and cash equivalents $ 130,285 $ — Prepaid expense 360,000 — Current assets 490,285 — Prepaid expense long-term 660,000 —

View Full Filing

View this 10-Q/A filing on SEC EDGAR